NEW OPPORTUNITIES IN TREATMENT OF SEVERE SYSTEMIC TYPE OF JUVENILE ARTHRITIS
Abstract
Key words: children, juvenile arthritis, treatment, tocilizumab.
(Voprosy sovremennoi pediatrii — Current Pediatrics. – 2010;9(4):160-167)
About the Authors
R.V. DenisovaRussian Federation
E.I. Alexeeva
Russian Federation
A.O. Lisitsin
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
References
1. Cassidy J.T., Petty R.E. Juvenile idiopathic arthritis. In Cassidy JT, Petty RE, eds. Textbook of pediatric rheumatology. 5th ed. Philadelphia: WB Saunders. 2005.
2. Алексеева Е.И., Валиева С.И., Бзарова Т.М.. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2009; 8(5):14–25.
3. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников. Под ред. Баранова А.А. М. 2007; 368.
4. Алексеева Е.И. Валиева С.И., Апаева Д.В. и др. Эффективность пульс–терапии метотрексатом с циклоспорином при тяжелом системном варианте ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2008; 7 (1): 29–34.
5. Veldhuis G.J., Willemse PH.B., Sleijfer D.T. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J. Clin. Oncol. 1995; 13: 2585–2593.
6. Rothwell N.J., Busbridge N.J., Lefeuvre R.A., Hardwick A.J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1465–1469.
7. Castell J.V., Gomez-Lechon M.J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.
8. Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.
9. Ikebuchi K., Wong G.G., Clark S.C. et al. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 1987; 84: 9035–9039.
10. Kimura H., Ishibashi T., Uchida T. et al. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.
11. Tsigos C., Papankolaou D.A., Defensor R. et al. Dose-effects of recombinant human interleukin–6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.
12. Heliovaara M.K., Teppo A.M., Karonen S.L., et al. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes. Metab. 2005; 7: 729–736.
13. Cutolo M., Straub R.H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 2008; 7: 223–228.
14. Nishimoto N. Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008; 181: 151–160.
15. European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics. URL: http://www.emea.europa.eu/humandoes/PDFs/EPAR/RoActemra/H-955-PI-en.pdf.
16. Chugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis. URL: http://www.chugai-pharm.co.jp.
17. Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (Suppl. II): 550.
18. Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.
19. Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.
20. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.
21. Yokota S., Miyamae T., Imagawa T. et al.: Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.
22. Aoki C., Inaba Y., Ozawa R. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis [OP-0145]. Ann. Rheum. Dis. 2009; 68(Suppl. 3): 118.
23. Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 506.
24. Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68(Suppl.3): 719.
25. Giannini E.H., Ruperto N., Ravelli A., Lovell D.J., Felson D.T., Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40: 1202–1209.
26. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.
Review
For citations:
Denisova R., Alexeeva E., Lisitsin A., Valieva S., Bzarova T. NEW OPPORTUNITIES IN TREATMENT OF SEVERE SYSTEMIC TYPE OF JUVENILE ARTHRITIS. Current Pediatrics. 2010;9(4):160-167.
Email this article 
